A Computer-aided rational approach for the in silico generation of a TCR Peptide Mimetic Pharmacoligand as a potential chemo-modulator in Human Autoimmune Diseases.

Inflammatory Th1 cells reacting to tissue/myelin derived antigens likely contribute to the pathogenesis of diseases such as multiple sclerosis (MS), rheumatoid arthritis (RA), and psoriasis. One regulatory mechanism that may be useful for treating autoimmune diseases involves an innate second set of Th2 cells specific for portions of the T cell receptor of clonally expanded pathogenic Th1 cells. These Th2 cells are programmed to respond to internally modified V region peptides from the T cell receptor (TCR) that are expressed on the Th1 cell surface in association with major histocompatibility molecules. TB Mobile can now manage a small collection of compounds that can be imported from external sources, or exported by various means such as email or app-to-app inter-process communication. This means that TB Mobile can be used as a node within a growing ecosystem of mobile apps for cheminformatics. It can also cluster compounds and use internal algorithms to help identify potential targets based on. Here, in Biogenea we have for the first time discovered a a TCR Peptide comprising potential Therapy Mimetic Pharmacophoric activation in Human Autoimmune Diseases by using BiogenetoligandorolTM and a New target prediction and visualization drug discovery tools.